Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and ...

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

Increases speed to market for drug developers working on nucleic acid therapeutics.

The global proteinase K market is projected to grow from US$ 27.5 million in 2023 to US$ 43.9 million by 2033, at a CAGR of 4 ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Ultima Genomics, Inc., a developer of an ultra-high throughput next-generation sequencing (NGS) platform, today announced that its UG 100™ was selected as the sequencing platform to enable UK ...

Human Metapneumovirus (HMPV) primarily spreads through respiratory secretions from coughing or sneezing, close personal ...

Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm's expertise in customized nucleic ...

The UK Biobank project, announced today, aims to investigate how fluctuations in protein levels during mid- to late-life may influence <a target= ...